Founded in 1978 as a joint venture between Biocon Biochemicals Ltd, Ireland and the company led by Ms. Kiran Mazumdar-Shaw, a young Indian entrepreneur, Biocon long depended on the income from the production of enzymes and generic drugs. However, the competitive pressure from both within the country and from other emerging economies such as China is rapidly undermining the price level in these lines of business. In addition, in 2005, the adoption of the WTO TRIPS in India meant that generic drugs based on a strategy that many pharmaceutical and biotechnology companies in India have followed may not be viable anymore. To continue its current growth path, Biocon should consider moving on biogenerics manufacturer to become a global innovator biopharmaceuticals. Worried about the strategy in new industries, sheds light on the effects of clusters on the strategy and the impact of national and supranational factors on strategy. Leadership issues and low-cost strategies for diversification are also considered. "Hide
by Jeroen van den Berg, Michael Enright, Venkat Subramanian Source: University of Hong Kong, 48 pages. Publication Date: June 27, 2007. Prod. #: HKU657-PDF-ENG
Related Case Solutions & Analyses:
Solutions For Customer Complaints About Offshoring And Outsourcing Services
Investment Technology Group
Operational Capabilities: Hidden in Plain View
Retail Relay A
Future of Hybrid Electric Vehicles
Liquid Gold: Calambra Olive Oil (A)
Publishing Group of America (B)
Drugstore.com
Charles Schwab Corp. (A)
Strategic Countermoves: Coca-Cola vs. Pepsi, Spanish Version
